Home > Boards > US Listed > Biotechs >

Cellectar Biosciences Inc. (CLRB)

CLRB RSS Feed
Add CLRB Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 5/26/2020 3:38:35 PM - Followers: 117 - Board type: Free - Posts Today: 0

Image result for CELLECTAR


Product Pipeline

Multi-Asset Product Portfolio for Treatment of Various Cancers

Our proprietary phospholipid ether (PLE) platform technology features include the capacity to link to a wide variety of warheads, provide a significant increase in targeted oncologic warhead delivery and the ability to target all tumor cells. As a result, we're working to generate Phospholipid Drug Conjugates™ (PDCs) to treat a broad range of cancers with the potential to improve the therapeutic index of oncologic drug warheads, enhance or maintain efficacy while reducing adverse events by minimizing drug delivery to healthy cells, and increasing delivery to cancerous cells and cancer stem cells.

 

PDC Proprietary Product Pipeline

PDC PROGRAM WARHEAD/
MECHANISM OF ACTION
INDICATION DISCOVERY PRE-IND PHASE 1 PHASE 2 COLLABORATION
CLR 131 IODINE-131
DNA DAMAGE
MULTIPLE MYELOMA
DISCOVERY PHASE COMPLETE
PRE-IND PHASE COMPLETE
PHASE 1 PHASE COMPLETE
PHASE 2 PHASE IN PROGRESS
 
B-CELL LYMPHOMAS
DISCOVERY PHASE COMPLETE
PRE-IND PHASE COMPLETE
PHASE 1 PHASE COMPLETE
PHASE 2 PHASE IN PROGRESS
 
PEDIATRIC
DISCOVERY PHASE COMPLETE
PRE-IND PHASE COMPLETE
PHASE 1 PHASE IN PROGRESS
PHASE 2 PHASE NOT STARTED
University of Wisconson-Madison
HEAD & NECK
DISCOVERY PHASE COMPLETE
PRE-IND PHASE IN PROGRESS
PHASE 1 PHASE NOT STARTED
PHASE 2 PHASE NOT STARTED
Univeristy of Wisconsin-Madison
CLR 1900 PROPRIETARY
CELL CYCLE ARREST
SOLID TUMORS
DISCOVERY PHASE IN PROGRESS
PRE-IND PHASE NOT STARTED
PHASE 1 PHASE NOT STARTED
PHASE 2 PHASE NOT STARTED
 

Partnerships

PDC PROGRAM WARHEAD/
MECHANISM OF ACTION
INDICATION DISCOVERY PRE-IND PHASE 1 PHASE 2 COLLABORATION
CLR 1800 PROPRIETARY
TRANSLATION INHIBITION
SOLID TUMORS
DISCOVERY PHASE COMPLETE
PRE-IND PHASE IN PROGRESS
PHASE 1 PHASE NOT STARTED
PHASE 2 PHASE NOT STARTED
Pierre Fabre
CLR 2000 PROPRIETARY
CYTOSKELETON DISRUPTION
PERFORMANCE-BASED
DISCOVERY PHASE IN PROGRESS
PRE-IND PHASE NOT STARTED
PHASE 1 PHASE NOT STARTED
PHASE 2 PHASE NOT STARTED
Avicenna Oncology
CLR 2100 PROPRIETARY
RIBOSOMAL INHIBITOR
SOLID TUMORS
DISCOVERY PHASE IN PROGRESS
PRE-IND PHASE NOT STARTED
PHASE 1 PHASE NOT STARTED
PHASE 2 PHASE NOT STARTED
Onconova Therapeutics
CLR 2200 PROPRIETARY
TUBULIN DISRUPTION
SOLID TUMORS
DISCOVERY PHASE IN PROGRESS
PRE-IND PHASE NOT STARTED
PHASE 1 PHASE NOT STARTED
PHASE 2 PHASE NOT STARTED
Onconova Therapeutics
CLR 12120   SOLID TUMORS
DISCOVERY PHASE IN PROGRESS
PRE-IND PHASE NOT STARTED
PHASE 1 PHASE NOT STARTED
PHASE 2 PHASE NOT STARTED
oranomed

Proprietary Products

CLR 131

CLR 131 is a small-molecule, targeted PDC designed to deliver cytotoxic radiation directly and selectively to cancer cells. CLR 131 is our lead therapeutic PDC product candidate and is currently being evaluated in multiple Phase 2 and Phase 1 clinical studies. 
VIEW CANDIDATE

CLR 1700

CLR 1700 series is an internally developed PDC program leveraging a unique warhead targeting Burton tyrosine kinase (BTK) and designed to treat a broad range of hematologic cancers. The warhead provides further specificity by targeting the BTK pathway, which is upregulated in hematologic cancers versus in comparison to normal tissue. We believe that this additional level of targeting will allow us to provide a new drug candidate that has the ability to significantly improve patient outcomes. Leveraging our iterative discovery and screening process, we have been able to rapidly accelerate the development of this program. Currently marketed BTK inhibitors generate >$4B in revenues per year.

CLR 1900

CLR 1900 series is another internally developed proprietary PDC program leveraging a novel class of small molecule cytotoxic compounds as the warhead. The warhead functions by targeting a validated pathway that results in the inhibition of cell division and thereby killing the tumor cells. This series of molecules could produce a product candidate targeted to select solid tumors. Currently, the program is in early preclinical development.


Partnered Products

CLR 1800

CLR 1800 series is part of a collaborative PDC program with Pierre Fabre, the third largest French pharmaceutical company with an extensive oncology research and development infrastructure. The objective of the research collaboration is to design a library of PDCs employing Pierre Fabre's chemotherapeutics in combination with our proprietary cancer-targeting delivery vehicle. The newly developed PDCs may provide enhanced therapeutic indices to otherwise highly potent, non-targeted warheads through the targeted delivery to cancer cells. Significant progress has been achieved and the program continues to rapidly advance with a number of PDC molecules showing enhanced pharmacologic behavior over the parent compound alone.

CLR 2000

CLR 2000 series is part of a collaborative PDC program with Avicenna Oncology, a leading developer of antibody drug conjugates (ADCs). The objective of the research collaboration is to design and develop a series of PDCs utilizing Avicenna Oncology’s proprietary cytotoxic warhead. Although Avicenna Oncology is a leading developer of ADCs, this collaboration was sought as a means to overcome many of the challenges associated with ADCs, including those associated with the targeting of specific cell surface epitopes.

CLR 2100 and 2200

CLR 2100 and 2200 series are part of a collaborative PDC programs with Onconova Therapeutics, Inc., a biotechnology company specializing in the discovery and development of novel small molecule cancer therapies. The collaboration is structured such that we will design and develop a series of PDCs utilizing different small molecules that Onconova Therapeutics is developing as the warheads with the intent to show improved targeting and specificity to the tumor. Onconova Therapeutics has previously taken at least one of the molecules into Phase 1 clinical trials.

CLRB
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#7980   Company selling shares, most likely. Most bios are in S3lfMade 05/26/20 03:38:35 PM
#7979   Why did it take a nose dive on cash_cow1 05/26/20 12:08:02 PM
#7978   CLR 131 is a radiotherapy designed to directly S3lfMade 05/26/20 09:02:48 AM
#7977   $5 Clover study of CLR131? Crusader 05/26/20 08:51:22 AM
#7976   $CLRB , Great News !! TTIME 05/26/20 08:39:50 AM
#7975   How do you get in all this big Bula Vinaka 05/26/20 08:10:31 AM
#7974   LOL. Your present today is an algo G&T. crudeoil24 05/26/20 07:59:38 AM
#7973   Cellectar Receives FDA Fast Track Designation for CLR [SMART MONEY] 05/26/20 07:49:33 AM
#7972   CEO needs to be Fired,he done Zero except Sunofwolf 05/13/20 08:46:49 AM
#7971   Before the well is poisoned more Crusader 05/09/20 04:07:58 PM
#7970   Worthless company. Sunofwolf 04/25/20 05:05:43 PM
#7969   This company's sells shares to pay for everything, Sunofwolf 04/15/20 03:59:10 PM
#7968   Love the simplicity of their drug, but still Sluicebox 04/14/20 11:42:13 AM
#7967   Ha Ha this junk is done! Sunofwolf 03/16/20 10:26:59 PM
#7966   Down a 100% from a fake high-this company Sunofwolf 03/13/20 08:52:07 AM
#7965   Good go to nothing! Sunofwolf 03/09/20 10:10:13 AM
#7964   no one will even Mod this company anymore. Sunofwolf 03/01/20 08:41:17 AM
#7963   gov allows these phony companies to exist-Snake Oil. Sunofwolf 03/01/20 08:37:19 AM
#7962   100% cash-won't trade anything anymore to these crooks! Sunofwolf 02/28/20 12:22:37 PM
#7961   Projected for a strong rebound zigland 02/19/20 06:04:45 PM
#7960   BAD NEWS COMING NEXT HOUR: Crusader 02/19/20 09:44:46 AM
#7959   BAD NEWS COMING NEXT HOUR: Crusader 02/19/20 09:44:41 AM
#7958   Bingo ! Crusader 02/14/20 10:59:23 AM
#7957   $3 price per share? Accumulation! Crusader 02/14/20 10:05:34 AM
#7956   UBS Switzerland buying CLRB: Crusader 02/13/20 11:40:52 PM
#7955   6 more days to wait for fog to clear: Crusader 02/13/20 03:59:41 PM
#7954   That’s the plan. 99% of biotechs in murocman 02/09/20 12:40:52 PM
#7953   get your money then drop the hammer. Sunofwolf 02/08/20 10:59:05 PM
#7952   Catalyst coming up. I think not. GLTU, Murocman murocman 02/08/20 07:07:39 PM
#7951   Watch out at any trading day this stock Sunofwolf 02/08/20 05:40:56 PM
#7950   this stock is not worth what its trading Sunofwolf 02/07/20 08:54:06 AM
#7949   X$2.80 close after hours market 2/4/20... Crusader 02/04/20 10:57:39 PM
#7948   $2.78 morning high; who is accumulating here? Crusader 01/29/20 10:54:42 AM
#7947   For cheap LEVERAGE: Remember CLRBZ Crusader 01/28/20 10:44:50 AM
#7946   There's something happening here Crusader 01/27/20 03:30:16 PM
#7945   time for the company to sell out the investor! Sunofwolf 01/25/20 06:46:16 AM
#7944   another stock reverse can happen at any time Sunofwolf 01/24/20 02:46:30 PM
#7943   Happy Hour open price $2.75 pps, Crusader 01/21/20 10:10:55 AM
#7942   Crusader, great post.. thank you!! Keep them coming.. Jakhoub 01/17/20 03:22:47 PM
#7941   WHere is the BOTTOM LINE of CLRB for Crusader 01/16/20 01:57:27 PM
#7940   Latest CLRB DATA PRESENTATION: Crusader 01/14/20 06:39:24 PM
#7939   WHY HIRE A CHIEF MEDICAL RESEARCH OFFICER Crusader 01/12/20 10:06:48 PM
#7938   Still lining their FDA ducks up: Crusader 01/06/20 02:40:31 PM
#7937   January promised data release? January 13-15, 2020? Crusader 12/20/19 05:03:30 PM
#7936   I don't believe anything this company puts out. Sunofwolf 12/17/19 08:14:45 AM
#7935   20 people in clinical trial and to more Crusader 12/16/19 09:37:13 AM
#7934   TWO PEOPLE?? Crusader 12/10/19 04:10:07 PM
#7932   CLRB ASH Presentation 12/7/19 Abstract: Crusader 12/02/19 03:19:23 PM
#7931   Above $2 where I belongs Crusader 12/02/19 11:54:34 AM
#7930   Here comes $2.00 per share, Crusader 11/29/19 12:16:33 PM
PostSubject